Ibrutinib is indicated in Europe for the treatment of several B-cell malignancies, including chronic lymphocytic leukaemia (CLL). However, despite the high efficacy and favourable toxicity profile of ibrutinib, recent data suggest that it is not always administered optimally in clinical practice, with an increased tendency for dose reduction and a higher frequency of discontinuation. An expert panel of European haematologists was convened to identify practical issues pertinent to physicians involved in the therapeutic management of ibrutinib-treated CLL patients and here we outline the findings. Practical management recommendations are given for treating patients with ibrutinib and clinical considerations for the management of adverse events (AEs) that can be associated with ibrutinib treatment are addressed. This article highlights that patients should be monitored for treatment emergent adverse events, most of which are mild, transient and generally occur early in therapy and that, even with more challenging AEs, patients can often be maintained on therapy with minimal disruption through careful management. The necessity to use the correct ibrutinib dose, along with increased awareness, vigilance, mitigation and management of AEs, are all recommended to maximise outcomes for CLL patients treated with ibrutinib.
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Ibrutinib, a potent, small-molecule inhibitor of Bruton tyrosine kinase (BTK), is a paradigm shifting agent in many Bcell malignancies. However, despite its high efficacy and favourable toxicity profile, recent data from general practice would indicate that it is not always administered optimally. Hence, this article, based on the result of the discussions of an expert panel, is intended as a practical guide for haematologists and other physicians who might treat patients with ibrutinib. We aim to explain the efficacy and side-effect profile of ibrutinib in order that physicians can support their patients and maximise the clinical benefits by using the drug in the safest, most appropriate way.
Bruton tyrosine kinase is an important signalling molecule of the B-cell receptor (BCR) and cytokine receptor pathways that is implicated in the pathogenesis of several B-cell malignancies (Honigberg et al, 2010; Ponader et al, 2012; Byrd et al, 2013) . Ibrutinib (Imbruvica TM ) is indicated in Europe for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) as a single agent; who have received at least one prior therapy as a single agent or in combination with bendamustine and rituximab; relapsed or refractory mantle cell lymphoma and patients with Waldenstr€ om macroglobulinaemia (WM) who have received at least one prior therapy, or in first-line treatment for WM patients unsuitable for chemo-immunotherapy (https://www. medicines.org.uk/emc/medicine/29383). Our focus is on CLL, where ibrutinib is predominantly used as a single agent, but the recommendations may be applicable across all indications. Although ibrutinib has also been shown to be beneficial for patients with CLL that have del(17p) or TP53 mutation who do not respond well to conventional chemoimmunotherapy (O'Brien et al, 2016a) , we concentrate on the broader patient population covered by the European label.
Single-agent ibrutinib has been evaluated in two Phase III, open-label, randomised, multicentre studies in CLL and small lymphocytic lymphoma patients who were either treatment-na€ ıve [RESONATE-2 (PCYC-1115)] or previously treated and ineligible for purine analogue therapy [RESONATE (PCYC-1112) ] . In RESONATE-2, single-agent ibrutinib was superior to singleagent chlorambucil for both progression-free survival (PFS) and overall survival (OS). In RESONATE, single-agent ibrutinib was superior to single-agent ofatumumab for both PFS and OS, with both studies showing depth of response improving over time. In both studies ibrutinib proved superior the comparator arm, despite there being considerable cross-over, and adverse events (AEs) associated with singleagent ibrutinib were manageable and did not frequently result in dose reduction or treatment discontinuation.
The 5-year follow-up data from a Phase Ib/II fixed-dose study of ibrutinib in CLL (PCYC-1102) have been reported, demonstrating impressive outcomes across various lines of treatment (O'Brien et al, 2016b) . Patients treated with ibrutinib in the first-line setting had a 92% 5-year PFS and OS rate and relapsed/refractory patients had 5-year PFS and OS outcomes of 43% and 57%, respectively. These data show the longest follow-up available for any novel agent in CLL and demonstrate that most ibrutinib-related AEs are transient and reduce over time. Additionally, up to 4 years follow-up data was also recently published for RESONATE showing sustained benefit in PFS and OS in the Phase III setting . At the time of follow-up, approximately half the patients were still on therapy, with the most common reasons for discontinuing ibrutinib being progression (27%) and AEs (12%). The most common grade ≥3 haematological AEs were neutropenia, anaemia and thrombocytopenia, and the most common grade ≥3 non-haematological AEs were pneumonia, hypertension, urinary tract infection and diarrhoea .
Most of the AEs observed in the ibrutinib clinical trials occurred early in treatment, usually transiently and incidence reduced over time (O'Brien et al, 2016b) . However, recent literature on the use of ibrutinib outside clinical trials indicates an increased tendency for dose reduction and a higher frequency of discontinuation than observed in clinical trials (Parikh et al, 2015; Ghia & Cuneo, 2016; UK CLL Forum, 2016; Winqvist et al, 2016) . Given that long-term follow-up in clinical trials demonstrates that ibrutinib has a favourable toxicity profile (O'Brien et al, 2016b; Moreno et al, 2017) , it is important for healthcare professionals to understand how they can manage patients in their daily practice in order to maximise clinical outcomes.
Methods
An expert panel of European haematologists was convened in November 2016 with the objectives of identifying practical issues pertinent to all physicians involved in the therapeutic management of ibrutinib-treated patients and to generate best practice recommendations, from a haematologist's perspective, for the management of specific AEs that might occur during therapy, thus ensuring patients that derive the maximum clinical benefit from ibrutinib. All experts that took part in the meeting had extensive experience of treating patients with ibrutinib and, as such, the meeting focussed on their collective review of several patient case studies to ascertain how they would optimise outcomes for patients on ibrutinib.
Results

The patient population and suitability for ibrutinib therapy
Chronic lymphocytic leukaemia primarily affects older people who often have pre-existing medical conditions and co-medications, in addition to disease related immunosuppression and myelosuppression (Stauder et al, 2016) . Consequently, it is important to know a patient's history as fully as possible, such as prior response to therapy, including toxicities, a full list of concomitant medication and co-morbidities. Patients with prior evidence of hypertension, cardiovascular (CV) disease and increased risk of bleeding may also have additional medical considerations. It is recommended that all patients should be given a CV assessment [e.g. family history, existing hypertension, heart rate, electrocardiogram (ECG) and other risk factors for CV diseases] before initiating ibrutinib. Patients should subsequently be monitored regularly by pulse and auscultation, particularly within the first 6 months. Routine laboratory testing, including full blood counts and general biochemistry, should also be completed.
It is also important to ensure that there is no evidence of Richter transformation (RT), so patients who have night sweats, elevated lactate dehydrogenase (LDH), or increasing lymphadenopathy at single sites should be fully evaluated, particularly in heavily pre-treated patients and those with del (17p). We recommend that in such cases, a positron emission tomography -computed tomography (PET-CT) scan is performed, and patients with an elevated standardised F-fluorodeoxyglucose (FDG) uptake value of five or more should be followed up, where possible, with a tissue biopsy of the most active lesion.
Practical management of patients on ibrutinib
Initiation of therapy. The recommended starting dose of ibrutinib for the treatment of CLL is 420 mg, three capsules taken at the same time once daily, and treatment should continue until disease progression, or until it is no longer tolerated by the patient. As efficacy has been established at 420 mg in CLL, and the occurrence of AEs have not been shown to be dose-dependent and can generally not be predicted, there is no evidence to support initiating ibrutinib at a lower dose, unless there is the possibility of a drug-drug interaction as discussed below.
Pharmacokinetic/pharmacodynamic studies show that the optimum receptor occupancy is obtained with 420 mg ibrutinib (Advani et al, 2013; Byrd et al, 2013) . In addition, subgroup analyses data from the RESONATE trial suggest that variable ibrutinib dosing may impact on PFS . Therefore, we recommend that the dose of ibrutinib should not be withheld or reduced unless there is a clinically important reason to do so, such as concomitant medications. If dose interruption and modification is deemed necessary, adjustments should only be made in line with the scheme provided in the ibrutinib summary of product characteristics (Fig 1) , from which the favourable outcomes in RESONATE and RESONATE-2 were achieved. Deviation from this scheme should be avoided as there are no published data on the efficacy of ibrutinib using alternative dose reduction schemes.
Drug-drug interactions (DDI). Like many drugs, ibrutinib is primarily metabolised in the liver, by cytochrome P450 enzyme 3A4 (CYP3A4), which increases the potential for DDI (de Zwart et al, 2016) . In a recent analysis of 118 ibrutinibtreated patients with CLL, 64% of patients were found to be taking medications that could increase ibrutinib levels (and potentially, toxicity) and 3% were on drugs that could decrease ibrutinib efficacy (Finnes et al, 2017) . Therefore, concomitant use of ibrutinib with strong or moderate CYP3A4 inhibitors/inducers should be avoided wherever possible. Table I shows a list of common drugs that are strong or moderate CYP34A inducers/inhibitors. If co-administration of ibrutinib with strong or moderate CYP3A4 inhibitors is being considered, the necessity/benefit of continuing concurrent therapy should be discussed with the patient's primary physician and alternative options that do not interact with CYP3A4 should be explored. If a decision is made to administer a concomitant strong or moderate CYP3A4 inhibitor the dose of ibrutinib should be reduced to 140 mg once daily (one capsule) and patients monitored closely. Withholding treatment during this period is not recommended as extended interruptions have been shown to be detrimental to patient outcomes .
There is in vitro evidence to indicate that ibrutinib is an inhibitor of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), although there is no supporting clinical data. To minimise the potential for interactions, it is recommended that P-gp and BCRP substrates with a narrow therapeutic range should be given at least 6 h before or after ibrutinib (https://www.medicines.org.uk/emc/medicine/ 29383). Caution is advised when patients are referred for treatment, and all treating physicians should be made aware of the potential for DDIs so that they can make treatment decisions accordingly. We strongly advocate careful and continuous vigilance in monitoring of concurrent, or subsequently introduced medication, particularly for elderly patients where polypharmacy may be a challenge. Furthermore, consultation and close collaboration with pharmacists is encouraged to prevent DDIs and mitigate the potential for side effects. 
Discontinue ibrutinib therapy
Withhold ibrutinib therapy until toxicity is resolved to grade 1 or baseline (recovery) 1st occurrence of new or worsening grade ≥3 nonhaematological toxicity, grade ≥3 neutropenia with infection or fever, or grade 4 haematological toxicities (specifically the release of lymphocytes from the lymph nodes), upon the addition of (BCR inhibitors, such as ibrutinib or idelalisib, and is now widely recognised as an on-target class effect (Herman et al, 2014) . BCR inhibitor-induced lymphocytosis is not a sign of progressive disease and does not predict for patients who are likely to relapse. This has also been repeatedly shown in clinical trials through cumulative general practice experience (Honigberg et al, 2010; Herman et al, 2014; Hallek, 2015) . Similar to lymphocytosis observed in patients off therapy, ibrutinib-induced lymphocytosis is predominantly transient (although it can persist for many months), does not affect PFS and has not been associated with clinical AEs (Woyach et al, 2014; Byrd et al, 2015) . Prolonged lymphocytosis may be the first sign of activity of the agent and may be associated with better outcomes, although longer follow-up is required to validate observed trends (Woyach et al, 2014) . The use of debulking treatments is not justified. In particular, leucostasis has not been reported in ibrutinib-induced lymphocytosis in CLL, even in patients who experience extremely high lymphocyte counts above 500 9 10 9 /l. Similarly, lymphocytosis is not associated with an increased risk of tumour lysis syndrome. In addition, patients commencing ibrutinib with very high lymphocyte counts do not require any particular precautions, however some authors would consider allopurinol at treatment initiation for these patients. In the exceedingly rare event of leucostasis, appropriate measures should be applied.
Compliance. Based on previous experience, patient compliance to therapy often decreases over time as patients become less symptomatic. Therefore, it is worth emphasising that patients should be motivated and receive continuous support during therapy in order to benefit from the long-term efficacy and disease control shown in randomized trials. Patients should be made aware of the risk: benefit ratio before starting therapy. We have observed that educating patients using lay terms about how their medication works will often improve compliance. Explaining the basic premise that the enzyme will be re-synthesised regularly can be beneficial in helping patients understand the importance of taking their medicine daily. Also, the explanation that the continuous use of the drug may indeed improve their response can be beneficial to keep the patients on treatment. The authors find it very useful to refer to the data from RESONATE-2 study where the frequency of complete responses increased with time from 7% to 18% during 2 years of follow-up , as well as the HELIOS study, where, after bendamustine and rituximab (BR) the continuous administration of ibrutinib alone improved the minimal residual disease negativity rate, from 0Á7% at the end of the six cycles of chemoimmunotherapy to 26% at 3-year follow-up (Fraser et al, 2016) . Improvement of patient compliance levels is likely to also be achieved by the alleviation of non-haematological side effects as described below. To ensure adequate compliance and tolerability, we recommend that responses to therapy should be monitored more intensively early in treatment (e.g. monthly for the first 3 months), before being extended (e.g. to 3-monthly assessments). Shatzel et al (2017) recently published a comprehensive set of recommendations on management and risk reduction strategies for ibrutinib-associated bleeding, atrial fibrillation (AF) and concomitant use of antithrombotic agents. While we will cover some of the same topics and provide our collective opinions from a European perspective herein, we fully endorse many of these recommendations and encourage readers to consult the full text for additional details.
Clinical considerations on the managements of AEs
Bleeding. Bruton tyrosine kinase has a vital role in glycoprotein VI signalling and inhibition has been shown to inhibit collagen-mediated platelet aggregation. This on-target effect has been observed in vivo (Kamel et al, 2015) because ibrutinib has been associated with an increased risk of any grade bleeding since the completion of early phase clinical trials (Byrd et al, 2013; Wang et al, 2017) . Most bleeding AEs observed in the clinical studies were grade 1-2, occurred early, required no dose interruption or dose modification, improved and frequently disappeared over time. The incidence of new emergent bleeding AEs also decreased significantly over time, being less frequent after the first 6 months of therapy (Jones et al, 2017) . Petechia, contusion, epistaxis and bruising have been some of the most common bleeding AEs observed in patients receiving ibrutinib and, notably, ibrutinib-related haemorrhagic events are seen in patients both with and without thrombocytopenia. Bleeding is generally manageable if physicians are well informed about the potential for bleeding to occur and patients are informed in advance to avoid any unease. Investigation into symptomatology is recommended for patients with known history of bruising; however, minor bleeding events, such as bruising or a history of minor bleeding, is not a reason to interrupt or reduce the dose of ibrutinib. Haematuria has also been observed during early clinical experience with ibrutinib (Wang et al, 2017) . Patients with haematuria should be checked for other underlying causes and a urology consultation should be considered if haematuria is persistent. While it is not possible to predict what will happen in any individual patient, there is no evidence to support initiating ibrutinib at a lower dose for a patient with a history of minor bleeding. Major haemorrhage (grade ≥3 AEs, including intracranial haematoma and gastrointestinal haemorrhage) has also occurred in ibrutinib-treated patients in clinical trials but there is currently no evidence to suggest a correlation between low grade bleeding events and the major bleeding events observed with ibrutinib. The proportion of ibrutinibtreated patients who experienced major haemorrhage ranges from 1% to 7% in CLL clinical trials (Byrd et al, 2013 Burger et al, 2015) . A recent systematic review and meta-analysis of observational studies and randomised control trials reported a relative risk of major bleeding of 1Á66 for the ibrutinib arm versus the comparator arm (P = 0Á07) (Caron et al, 2017) . However, it should be stressed that this analysis is limited and physicians should remain aware of the potential for major bleeding events and should evaluate the risk in each individual patient.
In the event of a major bleed, steps should be taken to understand the cause. If an association with ibrutinib is suspected, it is recommended that ibrutinib is withheld while investigations are performed. At this time, anticoagulant and antiplatelet treatment should be reviewed and where appropriate, stopped. If the site of bleeding is non-central nervous system (CNS), platelet therapy should be initiated, even in patients who are not thrombocytopenic. There are no strong recommendations in the event of CNS bleeds and these should be assessed on a patient-by-patient basis. However, generally, platelet transfusions are not advised for bleeding events of this nature (Shatzel et al, 2017) . In patients undergoing surgery, ibrutinib should be withheld for 3-7 days preand post-surgery, dictated by the risk level for bleeding (https://www.medicines.org.uk/emc/medicine/29383) to allow time for the reversal of antiplatelet effects. In the event of emergency surgery, a platelet transfusion (to receive 50% fresh platelets) is appropriate, taking in to account the timing of the last dose and the half-life of ibrutinib (Levade et al, 2014; Shatzel et al, 2017) . Concomitant medications should also be reviewed based on the risk of bleeding.
If it is considered safe to do so, the decision may be made to re-start ibrutinib; however, in the interim, alternative treatment strategies should be discussed. If the patient is unable to restart ibrutinib, a suitable alternative should be explored.
Atrial fibrillation. Atrial fibrillation is common in elderly patients, such as those who develop CLL, and incidence increases with age (Benjamin et al, 1998) . However, in clinical trials, the incidence of AF was increased on ibrutinib when compared to comparator groups Burger et al, 2015; Chanan-Khan et al, 2017; Dreyling et al, 2017) . In a pooled analysis of 1505 patients across four ibrutinib clinical trials (756 ibrutinib alone or in combination with BR), most AF events typically occurred within the first 6 months after initiation of ibrutinib therapy and continued at a low rate over time. Median time to onset of an AF event at initial follow-up (16Á6 months) was 2Á8 months in the ibrutinib arm and 2Á0 in the comparator arm. At a later follow-up of 36 months, the median time to an AF event for the ibrutinib arm extended to 5Á7 months. At the time of first analysis the incidence of AF was 6Á5% in the ibrutinib arm versus 1Á2% in the comparator arm, which, at the later follow-up, increased to 10Á4% in the ibrutinib arm. At the extended follow-up, there was no comparator data to report as the trials had already reached their primary endpoint.
The median duration of AF in both arms was 3 days and events were generally manageable, with only 14Á3% of patients who developed AF discontinuing ibrutinib therapy, which subsequently decreased to 9% with extended follow-up (<1% of total population). Approximately 50% of patients needed no change in dose or dose interruption. Most patients in the pooled analysis who had independent risk factors (identified by multivariate analysis) for developing AF, such as age over 65 years or prior history of AF, did not develop AF within the observation period. The only clinical significant sequelae to occur at a higher rate in the ibrutinib arm versus comparator was hypertension (P < 0Á0001); however, clinically significant sequelae were more frequently observed in those with multiple AF events, an observation seen more frequently with patients on ibrutinib, who often had predisposing medical history and relevant comorbidities. It should be noted that experiencing AF would appear not to impact PFS for patients taking ibrutinib .
Outside the clinical trial setting, incidence of AF may be slightly higher due to increased comorbidities and a less tightly controlled setting (Thompson et al, 2016; Wiczer et al, 2016) . As AF is frequent in elderly CLL patients , prior history of AF and the potential for developing AF should not deter physicians from considering ibrutinib for their patients.
Furthermore, physicians should always consider the possibility of AF in patients who develop CV/respiratory symptoms while taking ibrutinib and have an ECG performed. If a patient does develop grade ≥3 AF, ibrutinib should be temporarily withheld and AF managed with the advice of a cardiologist or according to the institution's internal procedures.
The panel stated that they would refer patients to cardiology for rate and rhythm control to manage the condition. Cardiologists should be made aware of the potential for DDI if they decide to use drugs that interact with CYP3A4, such as amiodarone. Although the median duration of ibrutinibrelated AF was relatively short, some patients may experience prolonged AF and collaboration with cardiology will be important. A cardiologist should be engaged at the time of initiating anticoagulation (AC) therapy, beside referring to European Society of Cardiology (ESC) guidelines for the management of AF (Kirchhof et al, 2016) because different subtypes of AF carry different embolic risks. For patients who develop AF, ibrutinib should either be maintained or withheld and restarted as soon as the cardiac situation is normalised or under control, depending on the severity of AF. For those patients who have had treatment withheld, the risk:benefit ratio should be evaluated for each patient when ibrutinib is introduced by considering the level of disease control that the patient had prior to the AF event. However, it should be noted that not all patients will require AC therapy.
Concomitant anticoagulation and antiplatelet therapy. Anticoagulants and antiplatelets are important considerations for ibrutinib therapy, given that CLL typically occurs in an elderly patient population that is at an elevated risk for CV complications, and both classes of drug are associated with an increased risk of bleeding (Makris et al, 2013) . The rate of all-grade bleeding AEs in patients on ibrutinib is generally increased compared to comparator arms but appears similar with or without concomitant anticoagulants/antiplatelets in post-hoc analyses of clinical trial data Jones et al, 2017) . In clinical trials, the use of antithrombotic agents was common, with over 50% of patients on ibrutinib receiving an anticoagulant, antiplatelet or a combination of both (Jones et al, 2017) . Outside the clinical trial setting, published data shows a similar rate of serious haemorrhagic events between patients taking ibrutinib plus an antithrombotic agent (2Á6%) and the overall ibrutinib population (1Á6%) . However, patients receiving ibrutinib and concomitant anticoagulants/antiplatelets should always be closely monitored for the risk of bleeding. Although it is important to avoid polypharmacy in elderly patients whenever possible, the risk to the individual patient should always be considered, and if anticoagulants and/or antiplatelets are clearly indicated, physicians should carefully evaluate their approach to therapy, including the choice of antithrombotic agent. It is therefore equally important for physicians to fully understand the rationale for patients who have previously started an anticoagulant or antiplatelet beforehand and calculate if the medication is still required.
Antiplatelets. Given the age and comorbidity of patients with CLL, many patients receive antiplatelet agents prior to commencing ibrutinib. Aspirin is the most commonly used antiplatelet agent, which can be continued when ibrutinib is started, but patients should be closely monitored and if there is excessive bruising or bleeding then consideration should be given to stopping the aspirin. It has been proposed that discontinuing aspirin in patients who start ibrutinib could be a legitimate strategy due to the inherent antiplatelet activity of ibrutinib; however, there is no clinical evidence to support this (Mulligan et al, 2016) .
Ibrutinib may be given alongside other antiplatelet agents; however, patients who are receiving 'dual' antiplatelet therapy (DAPT), such as aspirin and clopidogrel, tend to bleed excessively when ibrutinib is started due to the inhibitory effect on multiple platelet aggregation pathways. Given the antiplatelet nature of ibrutinib, some of the present authors conclude that consideration should be given to stopping one of the antiplatelet agents at the time of starting ibrutinib, particularly if there are limited effective antineoplastic agents available.
Another recommendation would be to temporarily withhold ibrutinib if short-term DAPT is indicated, reinstating immediately upon completion of DAPT. Where long-term DAPT is indicated, alternative options should be explored. Consistently, patients should be cautioned against using nonsteroidal anti-inflammatory drugs, fish oils and vitamin E (https://www.medicines.org.uk/emc/medicine/29383).
Anticoagulants. There are no formal restrictions on the concomitant use of anticoagulants with ibrutinib. However, following initial clinical experience with ibrutinib and a review of data in the early studies, use of vitamin K antagonists (VKA) was excluded from ibrutinib clinical trials (Byrd et al, 2013; Burger et al, 2015; Wang et al, 2017) and there are few data available to describe the clinical experience with ibrutinib and concomitant VKA. Conversely, non-VKA, including novel oral anticoagulants (NOACs) were permitted in the clinical trials that led to regulatory approval of ibrutinib for the treatment of CLL. The panel generally agreed that NOACs were the most appropriate method of anticoagulant and it is likely that as practice evolves, NOACs will replace warfarin as the mainstay anticoagulant in clinical practice. However, if the decision is taken to use a VKA with ibrutinib, then this should be undertaken with careful International Normalised Ratio (INR) monitoring.
When considering treatment options for CV diseases, where possible, physicians should follow the ESC guidelines without modification and work closely with a cardiologist. For patients who develop AF while on ibrutinib, the approach to anticoagulants/antiplatelets can be based on the risk of cardioembolic stroke as follows: for patients with a CHA 2 DS 2 VASc score of 0, no anticoagulants/antiplatelets are required; for patients with a CHA 2 DS 2 VASc score of 1, a NOAC should be considered and for patients with a CHA 2 DS 2 VASc score of ≥2, a NOAC is preferable to VKA. Aspirin currently has no role in stroke prevention in AF and, where possible, concomitant antiplatelets should be discontinued (Kirchhof et al, 2016) .
Based on the evidence from the Phase III trials, it is recommended that patients are maintained on ibrutinib where possible, using the dose modification scheme within the ibrutinib summary of product characteristics (https://www.medic ines.org.uk/emc/medicine/29383). However, it is prudent for physicians to plan potential alternative treatment strategies in case a patient's AF cannot be fully controlled and the risk: benefit ratio dictates that they need to discontinue ibrutinib. Patients receiving concomitant anticoagulation should be closely followed, particularly during the early phase of treatment.
There is currently a lack of direct clinical evidence to demonstrate which NOAC should be the preferred partner of choice for ibrutinib. When selecting an anticoagulant, consideration should be given to the potential for DDIs, particularly as polypharmacy can be a challenge in this patient group and the major clearance route for ibrutinib is via CYP3A4 metabolism and in vitro ibrutinib has been shown to inhibit P-gp.
Rivaroxaban, apixaban and ibrutinib are all metabolised by CYP3A4 and are also substrates or an inhibitor of the efflux transporter P-gp (http://www.ema.europa.eu/docs/en_ GB/document_library/EPAR_-_Product_Information/human/ 002148/WC500107728.pdf; www.ema.europa.eu/docs/en_ GB/document_library/. . ./WC500057108.pdf; https://www. medicines.org.uk/emc/medicine/29383). Theoretically, if P-gp is inhibited and the CYP3A4 pathway is fully saturated, coadministered with multiple CYP3A4 substrates could lead to increased plasma concentration of apixaban or rivaroxaban; however, this is unlikely to be of clinical significance (Chai et al, 2017) . Certain anti-arrhythmic drugs also inhibit the CYP3A4 pathway, and dosing of ibrutinib, apixaban and rivaroxaban may need to be amended if prescribed together.
The pro-drug dabigatran etexilate (but not dabigatran) and edoxaban are both substrates of P-gp. Both are renally metabolised and therefore have no impact on the CYP3A4 pathway (http://www.ema.europa.eu/docs/en_GB/document_ library/EPAR_-_Product_Information/human/002629/WC500 189045.pdf; http://www.ema.europa.eu/docs/en_GB/docume nt_library/EPAR_-_Product_Information/human/000829/WC 500041059.pdf). Hypothetically, inhibition of P-gp by ibrutinib could affect the plasma concentrations of dabigatran and edoxaban but there is no clinical data to support this.
The lack of available clinical data in this setting make it difficult to show superiority of one NOAC over another when partnered with ibrutinib. When discussing current treatment practices, the authors did come to a consensus that apixaban and dabigatran were their two preferred NOACs of choice. The majority of the authors stated their preferred option would be apixaban, with most indicating they would prescribe a dose of either 2Á5 mg twice daily (BID) or 5 mg BID for patients on ibrutinib. Those authors who stated they would use the regular dose of 5 mg BID, would consider dose reduction in a variety of patient subgroups, such as those with renal insufficiency, weight <60 kg or age >80 years. The superior gastrointestinal side-effect profile of apixaban compared to other NOACs was a key consideration driving treatment choice.
Dabigatran was the second most popular NOAC, with the authors recommending administration at the standard dose of 150 mg BID. However, a reduced dose of 110 mg BID could be considered for patients at a high risk of bleeding or with renal insufficiency. Authors with a preference towards dabigatran stated the availability of an antidote (https://www. medicines.org.uk/emc/medicine/31243) and reduced potential for CYP3A4 interaction as a rationale for treatment choice. None of the authors highlighted rivaroxaban or edoxaban as their preferred partner NOAC for patients on ibrutinib.
Hypertension. Given that the median age of CLL diagnosis is >70 years (Nabhan et al, 2014; Li et al, 2015; Pulte et al, 2015; Miller et al, 2016) , patients who begin ibrutinib treatment often have a history of hypertension (Gillespie & Hurvitz, 2013; Thompson et al, 2016) . In a long-term follow-up study of single-agent ibrutinib, the incidence of grade ≥3 hypertension was 26% in treatment-na€ ıve patients and 22% in relapsed/refractory patients, and this rate remained constant or increased over time . If a patient experiences hypertension or worsening hypertension during ibrutinib therapy it is important to both treat this and determine whether the cause is treatment-related or due to extraneous factors (such as renal or adrenal dysfunction). It is preferable to maintain the ibrutinib dose and vigorously treat the hypertension to minimise the risk of further complications, such as AF. Optimisation of hypertensive agents is strongly advised, using the joint recommendations outlined by the European Society of Hypertension (ESH) and ESC (Mancia et al, 2014) . When combining antihypertensive medication, it is preferable to prioritise medications that do not inhibit CYP3A4.
Infection. Immune deficiency, such as hypogammaglobulinaemia, is a hallmark of CLL and contributes to the relatively high rates of infection and morbidity in these patients (Morrison, 2009 ). Consequently, infections are common during treatment with traditional CLL therapy due to both diseaseand drug-related factors. Infectious prophylaxis was not mandated in clinical studies of ibrutinib and the most common infections in pivotal trials included pneumonia, upper respiratory tract infections, sinusitis and urinary tract infections Burger et al, 2015) . However, most infections occur early after initiation of ibrutinib therapy, decrease with time (Byrd et al, 2013; Burger et al, 2015; Moreno et al, 2017) and are inversely correlated with improvements in serum immunoglobulin A (IgA) (Sun et al, 2015) . Furthermore, clinically meaningful recovery of (humoral) immune function appears to occur on ibrutinib (Sun et al, 2015) and, given the link between CLL and immune dysregulation, it can be assumed that the infection rate will also decrease when ibrutinib is started in earlier lines of therapy in the CLL disease course (O'Brien et al, 2016b) . Given these data, the routine use of infectious prophylaxis for ibrutinib treatment is not recommended, especially in the firstline setting, but should be determined on a case-by-case basis depending on factors such as prior therapy, immune status, splenectomy and prior infections. However, prior to starting ibrutinib treatment, patients should be strongly encouraged to have relevant vaccinations (e.g. for influenza and pneumonia). The combination of sulfamethoxazole and trimethoprim may be appropriate for patients who have received previous chemoimmunotherapy.
Once ibrutinib therapy has been initiated, patients should be monitored for fever, neutropenia and infections as part of their routine check at every clinic visit and all treatmentemergent infections should be carefully assessed for aetiology, treated vigorously and the use of growth factors should be considered. Based on recent reports describing a small number of cases, physicians should be also be vigilant to exclude the possibility of opportunistic infections, such as Pneumocystis (jirovecii) pneumonia (PJP) Arthurs et al, 2017) ; however, prophylaxis for all patients is not recommended. For low-grade infections, the authors recommend continuation of ibrutinib therapy and dose adjustments need only be considered for the duration of anti-infective treatment if there is the potential for DDI with antimicrobial agents that are moderate/strong CYP3A4 inhibitors (e.g. clarithromycin, ketoconazole or voriconazole). For more severe infections (grade ≥3), ibrutinib treatment should be paused and steps taken (e.g. CT scans) to determine the cause of any unexplained fever or infection. Following resolution of the infection, ibrutinib should be reintroduced at the appropriate dose.
Arthralgia and myalgia. While incidences of arthralgia and myalgia (all grades) have been observed in clinical studies of ibrutinib (17% arthralgia and 10% myalgia) in RESONATE and 16% arthralgia in RESONATE-2 , an integrated safety analysis of pooled data from ibrutinib-treated patients in the RESONATE and RESONATE-2 studies demonstrated that arthralgia was mostly mild, relatively short-lived (55% of patients with arthralgia resolving with a median duration of 33 days) and frequently managed with additional concomitant medications . Indeed, in routine practice, myalgia and arthralgia are generally considered relatively mild idiosyncratic AEs. Although the incidence of arthralgia remains constant over time , in clinical practice patients often report these AEs following a prolonged period on ibrutinib therapy. The authors proposed that this increased reporting of arthralgia following prolonged ibrutinib therapy may be related to patients having achieved clinical response and an alleviation of disease-related symptoms, which, in turn, leads to them being more aware of their underlying arthralgia. However, it is important that patients are educated to report any signs of AEs throughout treatment.
We recommend that following discussion with the patient on the value of continuing ibrutinib therapy, those experiencing arthralgia/myalgia are treated with low dose analgesics in the first instance (e.g. paracetamol/acetaminophen), and the dose escalated based on individual patient needs. Options such as low-dose opioids or anti-epileptics should also be considered. The treatment of ibrutinib-associated AEs with nonsteroidal anti-inflammatory drugs can be challenging because of the potential for increased bleeding due to association between non-selective COX1/2 inhibition and a reduction in platelet function, so care should be taken to select agents that have shown the lowest levels of platelet inhibition (e.g. celecoxib, meloxicam and metamizole) (Shatzel et al, 2017) and confirm the actual need of pharmacological intervention. Dose reduction or discontinuation of ibrutinib therapy should be considered in severe cases after seeking advice from a rheumatologist and/or pain clinic on management options. Anecdotal feedback suggests drinks with high levels of quinine sulphate, such as certain brands of tonic water, have been successfully used to treat cramps and arthralgia and may be a consideration. However, it should be noted that, on extremely rare occasions, quinine has been associated with drug-induced thrombocytopenia (Lefkowitz & Shapiro, 1986) .
Care should be taken to investigate the potential for underlying conditions that may resemble arthralgia/myalgia. For example, at the 14th International Conference on Malignant Lymphoma, a case study was discussed around an episode of severe/acute gout with symptoms of arthralgia which was resolved with colchicine (Celltrion Healthcare, 2017).
Diarrhoea. Diarrhoea was among the most common AEs observed in ibrutinib clinical trials Burger et al, 2015) . However, it was generally mild, self-limiting (within about 3 weeks without therapy) and typically resolved without additional therapy or dose modification. Grade ≥3 diarrhoea occurred more frequently in the ibrutinib group than the comparator groups in the RESONATE (ibrutinib 4% vs. ofatumumab 2%) and RESONATE-2 studies (ibrutinib 4% vs. chlorambucil 0%) Burger et al, 2015) , but the incidence of grade ≥3 diarrhoea appeared to decrease over time O'Brien et al, 2016b) . Patients should be encouraged to maintain hydration levels, report any worsening of diarrhoea, particularly in the later months of treatment, and other potential causes of diarrhoea, such as cancer or infection, should be Optimising Ibrutinib Therapy Outcomes for CLL Patients ª 2018 John Wiley & Sons Ltd ruled out. Some patients in the ibrutinib clinical trials successfully received symptomatic management with anti-motility agents (such as loperamide), which was generally successful in treating diarrhoea once infectious aetiologies were ruled out (Badar et al, 2014; Burger et al, 2015) .
It should be noted that gastrointestinal problems associated with ibrutinib are usually transitory, unlikely to become severe and thought to be due to off-target effects. It is important that these relatively mild symptoms are considered separately from colitis, which is an unfortunate and severe side effect of some BCR inhibitors, particularly those targeting the PI3K pathway (Falchi et al, 2016) .
Rash. In Phase III clinical trials of ibrutinib in CLL, any grade rash was reported in 8% of patients in the RESONATE study and grade ≥3 rash was reported in 3% of patients in RESONATE-2 Burger et al, 2015) . While most of the current understanding of ibrutinib-associated rash comes from individual case reports (Mannis et al, 2015; Jensen et al, 2017) , reports of larger patient groups being assessed for clinicopathological features, treatment methods and outcomes are starting to emerge (Iberri et al, 2016) . It is the authors' experience that most patients who develop rash have prior history of hypersensitivity to other agents. Upon the appearance of rash, the authors recommend that steps are taken to determine whether the underlying cause is due to concomitant medications, infection or associated with ibrutinib treatment. Not all cases of confirmed ibrutinibassociated rash will require treatment (especially if the rash is haemorrhagic); however, if treatment is required, topical steroids and antihistamines should be given regardless of severity as they are beneficial in treating pruritus. Rash typically develops within the first few weeks of treatment and patients should be monitored in the days preceding this. Ibrutinib should not be withheld, as often the rash can be treated successfully. However, in severe cases of rash or if signs of intolerance appear, such as face or lip swelling and lip tingling, physicians should consider withholding ibrutinib and the patient be examined. Once the rash resolves, ibrutinib should be reintroduced at the appropriate dose. If the rash returns, ibrutinib can be stopped and re-initiated at a lower dose; however, if the rash is severe and persists following dose modification, an alternative therapy should be considered. If patients have a persistent rash that does not resolve, a skin biopsy should be taken for appropriate pathological assessments.
Fatigue. Any grade fatigue was reported for >20% of patients in both RESONATE and RESONATE-2 (28% and 30%, respectively). However, severe fatigue was only observed in the minority of cases (2% of patients with grade 3 or 4 fatigue in RESONATE and 1% of patients with grade ≥3 fatigue in RESONATE-2) Burger et al, 2015) . In an integrated safety analysis from RESONATE/ RESONATE-2, the median time until fatigue resolution was 57 days . The authors have seen very few patients with severe fatigue in clinical practice and it should be noted that fatigue may be a greater challenge in the very elderly. If a patient experiences severe fatigue on ibrutinib, ruling out other possible causes of the symptoms is recommended. It is the opinion of the authors that fatigue is likely to be a symptom of the underlying disease rather than specifically associated with ibrutinib therapy. This highlights the importance of correct dosing and maintenance of ibrutinib as, once the disease becomes under control, the fatigue may subside.
Autoimmune cytopenias. Ibrutinib treatment has been associated with a low rate of treatment-emergent autoimmune cytopenias (AIC), and a history of autoimmune haemolytic anaemia (AIHA) or direct antiglobulin test positivity does not predict the appearance of autoimmune cytopenia upon ibrutinib therapy Vitale et al, 2016) . Despite extensive experience with the drug, the authors have no personal experience of ibrutinib-emergent AIC; however, reports from the literature suggest that AIC flares can infrequently occur during the first weeks of ibrutinib treatment and may require additional treatment with or without the transient addition of other therapies targeted towards the autoimmune component of the disease (i.e. a combination of steroids and rituximab) (Vitale et al, 2016) . Management of AIC would appear feasible while on ibrutinib therapy. The treatment of underlying CLL is thought to be critical for long-term control of AIC and this hypothesis is supported by the fact that patients with existing AIC have been successfully treated with ibrutinib and subsequently discontinued AIC therapy Vitale et al, 2016) .
Management of patients starting to progress on ibrutinib treatment. Symptomatic improvement generally happens early after the initiation of ibrutinib therapy. However, some patients will become refractory to ibrutinib treatment and show signs of progressive disease (e.g. increasing white blood cell count and lymphadenopathy) (Woyach, 2017) . The identification of relapsing patients can be challenging and monitoring patients for signs of early progression is essential (Woyach et al, 2014; Ahn et al, 2017) .
Progression is often observed by the return of B-symptoms or cytopenia, but it is recommended that apparent progression is confirmed by ruling out a temporal increase in absolute lymphocyte count or nodal enlargement due to dose interruption or an infection. Patients with signs of progression, especially early in therapy, should be considered for the potential presence of RT (using PET-CT, nodal or other biopsies, bone marrow aspirates and blood smears). Where RT has occurred, patients should be treated in the same way as typical RT patients, according to institutional practice. Treatment options, including rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or other anthracycline-containing regimens are recommended, particularly if clonally unrelated to the CLL. 
Recommendation Prior to initiating ibrutinib therapy
• Physicians should take a thorough patient history and current concomitant medications • All patients should be given a thorough CV assessment and should then be regularly monitored by a physical examination • Prior history of AF or other and the potential for developing AF should not deter physicians from considering ibrutinib for their patients • Infectious prophylaxis should be determined on a case-by-case basis depending on factors such as prior therapy, immune status, splenectomy and prior infections • Patients should be strongly encouraged to have appropriate vaccinations Ibrutinib dosing
• The starting dose of ibrutinib for the treatment of CLL should be 420 mg QD and treatment should continue until disease progression, or it is no longer tolerated by the patient • The dose of ibrutinib should not be reduced unless there is a clinically important reason and adjustments should only be made using the defined scheme (Fig 1) • Ibrutinib should be withheld 3-7 days pre-and post-surgery depending on the bleeding risk
Monitoring
• All patients receiving ibrutinib should be monitored regularly for AF, bleeding and infection. This is particularly important if the patient has prior history of any of the above • Given the risk of emergent or worsening hypertension the patients should have their blood pressure monitored regularly when on ibrutinib • Patients on ibrutinib therapy should be routinely monitored for fever, neutropenia and infections • Patients with a prior history of AF should be monitored carefully during follow-up visits (especially within the first 6 months) by physical examination • Patients receiving concomitant AC and/or AP should be monitored closely • Response to therapy should be monitored more intensively during early treatment (e.g. monthly for 6 months), before being extended (e.g. to 3-monthly assessments)
Concomitant therapy
• Concomitant use of ibrutinib with strong or moderate CYP3A4 inhibitors/inducers should be avoided whenever possible. Dose reduction of ibrutinib should be performed with concomitant moderate/strong CYP3A4 inhibitors • Patients who develop AF should be stratified according to CHA 2 DS 2 VASc when considering AC: CHA 2 DS 2 VASc score of 0 ibrutinib without concomitant therapy CHA 2 DS 2 VASc score of 1 ibrutinib with AC considered CHA 2 DS 2 VASc score of ≥2 ibrutinib plus AC Physicians should engage a cardiologist regarding management of atrial fibrillation • Ibrutinib can be withheld during a short course of DAPT, but physicians should consider replacing ibrutinib with a different agent if long-term DAPT is indicated • Concomitant medications should be reviewed pre-and post-surgery, with adjustments considered based on the risk of bleeding Treatment-emergent adverse events
• Minor bleeding is not a reason to stop or reduce the dose of ibrutinib • Platelet therapy should be initiated for non-CNS major bleeding events, even in patients who are not thrombocytopenic • All treatment-emergent infections should be carefully assessed for aetiology, treated vigorously and the use of growth factors/IVIG considered • For low grade infections, ibrutinib therapy should be continued, with dose adjustments only considered for the duration of anti-infective treatment if there is the potential for DDI • For severe infections, ibrutinib should be withheld until the infection is resolved and appropriate treatment initiated • Patients experiencing arthralgia/myalgia should be treated with low dose analgesics in the first instance, and pain relief should be escalated based on individual patient needs • Physicians should seek advice from a rheumatologist and/or pain clinic on management options for patients with persistent arthralgia/myalgia • If a patient experiences hypertension or worsening of hypertension during ibrutinib therapy, physicians should continue therapy, determine whether the cause is treatment-related or due to extraneous factors and treat the hypertension accordingly (following ESH/ESC guidelines) • Patients who develop ibrutinib-emergent diarrhoea should continue ibrutinib therapy but should be encouraged to report any worsening, particularly in later months of treatment, and other potential causes of diarrhoea should be ruled out prior to symptomatic management with antimotility agents • Depending on severity, topical steroids and antihistamines may be required to treat rash, but stopping ibrutinib treatment is not advised except for the most severe cases of rash where physicians can consider withholding ibrutinib until the rash resolves • Ibrutinib should be continued if a patient experiences severe fatigue while on therapy and other possible causes of the symptoms should be ruled out Otherwise experimental approaches, such as rituximab plus lenalidomide, stem-cell transplant or, if available, enrolment on to a suitable clinical trial should be considered (Eyre & Schuh, 2017) . In the event that relapse has occurred, current evidence supports the continued use of ibrutinib until the patient is ready for the next therapy, because rapid disease progression has been observed in CLL patients upon ibrutinib discontinuation (Maddocks et al, 2015; Woyach, 2017) . Relapse may be due to mutation in the BTK binding site, changing the ibrutinib BTK inhibition from irreversible to reversible and PLCc2 mutation, activating the pathway irrespective of BTK inhibition. Treatment options for patients who have become refractory to/progressed on ibrutinib include enrolment on to clinical trials, treatment with agents with proven activity after ibrutinib, such as venetoclax (https://www.medicines.org.uk/emc/medicine/32650; Mato et al, 2017) or idelalisib plus rituximab (https://www.medic ines.org.uk/emc/medicine/29201; Mato et al, 2017) or standard chemotherapy approaches (Woyach, 2017) . As new BTK inhibitors become available it will be important to understand whether the progression is related to mutations in BTK or PLCc2 to help direct which future therapy to select following ibrutinib progression.
Discussion
Recent ibrutinib clinical trials have demonstrated clinically relevant benefits for both treatment-na€ ıve and relapsed/refractory patients with CLL, including significant improvements in OS and PFS compared with standard therapies and, overall, a favourable toxicity profile Byrd et al, 2015) . Importantly, ibrutinib has become an important treatment choice for patients with CLL in whom it has shown significant activity and is now included in both the European Society for Medical Oncology and National Comprehensive Cancer Network treatment guidelines Eichhorst et al, 2016; Wierda et al, 2017) . As such, ibrutinib constitutes a meaningful advancement in the treatment of CLL and these recommendations are a way to help healthcare professionals maximise the clinical benefit of ibrutinib for their patients (see Table II for a summary of key recommendations).
The authors are in full agreement that prior to starting ibrutinib, a full patient history and list of concomitant medications are critical to ensure patients are best positioned to derive maximum clinical benefit from the drug. Here, we have addressed some common treatment-emergent AEs that have been identified during the clinical development of ibrutinib and reaffirmed in post-marketing surveillance. The most frequent AEs associated with ibrutinib are mild and transient in nature, generally occurring during the early stages of therapy. However, even with more challenging AEs, discontinuing ibrutinib is not necessarily required, and with thorough careful management, patients can be maintained and experience positive outcomes.
In the cases described, the authors have focused on the necessity to use the correct ibrutinib dose, continued treatment and the minimal disruption of therapy to maximise the potential for a durable treatment-response. While it is always important for clinical decisions to be based on the individual risk profile for every patient, the authors believe that increased awareness, vigilance and management of side effects can contribute to optimised outcomes for CLL patients treated with ibrutinib. • Apparent progression of CLL should be confirmed by ruling out a temporal increase in absolute lymphocyte count or nodal enlargement due to drug holiday or infection and patients with signs of progression should also be investigated for the presence of Richter transformation, especially within the first years of therapy • If patients have confirmed progressive disease, ibrutinib therapy should be continued until the patient is ready to receive their next therapy has received honoraria and/or research funding from AbbVie, Gilead, Janssen, Mundipharma and Roche. Christian H. Geisler has served as consultant for Celgene, Janssen and Novartis. Paolo Ghia has received honoraria and/or research funding from AbbVie, Adaptive Biotechnologies, Gilead, Janssen and Roche. Peter Hillmen has received honoraria and/or research funding from AbbVie, Gilead, Janssen, Pharmacyclics and Roche. Carol Moreno has served as a consultant for Gilead and Janssen and has received research funding from Janssen and Roche. Stephan Stilgenbauer has received honoraria and/or research/travel funding from AbbVie, Amgen, Boehringer Ingelheim, Celgene, Genentech, Genzyme, Gilead, GSK, Janssen, Mundipharma, Novartis, Pharmacyclics and Hoffmann La-Roche.
